Clinical performance validation and four diagnostic strategy assessments of high-sensitivity troponin I assays

Abstract Acute coronary syndrome (ACS) includes conditions such as unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI). High-sensitivity cardiac troponin I (hs-cTnI) assays have been recommended as primary biomarkers for NSTEMI diagno...

Full description

Saved in:
Bibliographic Details
Main Authors: Junyi Wu, Yaotong Hua, Yilin Ge, Ke Chen, Siyu Chen, Jiashu Yang, Hui Yuan
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-99273-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849713079379558400
author Junyi Wu
Yaotong Hua
Yilin Ge
Ke Chen
Siyu Chen
Jiashu Yang
Hui Yuan
author_facet Junyi Wu
Yaotong Hua
Yilin Ge
Ke Chen
Siyu Chen
Jiashu Yang
Hui Yuan
author_sort Junyi Wu
collection DOAJ
description Abstract Acute coronary syndrome (ACS) includes conditions such as unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI). High-sensitivity cardiac troponin I (hs-cTnI) assays have been recommended as primary biomarkers for NSTEMI diagnosis due to their high sensitivity and specificity. However, there is no consensus on the optimal diagnostic strategy for early NSTEMI detection. This study aims to evaluate the diagnostic performance of four hs-cTnI-based strategies for suspected NSTEMI: Limit of Detection (LoB), Single Cut-off, hs-cTnI 0/1 h Algorithm, and hs-cTnI 0/2 h Algorithm, in a Chinese cohort and compare the performance of assays from different manufacturers. Performance verification was conducted, including LoB, LoD, LoQ, and precision analysis. Clinical samples from 267 ACS patients were analyzed using Hybiome hs-cTnI assays. Diagnostic accuracy was assessed based on sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1-score. The LoB strategy demonstrated 100% sensitivity but low PPV (14.0%). Both the hs-cTnI 0/1 h Algorithm and hs-cTnI 0/2 h Algorithm showed high diagnostic performance, with the 0/2 h algorithm providing the best overall. 89.0% accuracy, 93.3% sensitivity, and 73.68% F1-score. The hs-cTnI 0/2 h Algorithm offers the most reliable diagnostic performance for early NSTEMI diagnosis.
format Article
id doaj-art-3e1dcf3853bd445fb1e4085d6d6418db
institution DOAJ
issn 2045-2322
language English
publishDate 2025-04-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-3e1dcf3853bd445fb1e4085d6d6418db2025-08-20T03:14:03ZengNature PortfolioScientific Reports2045-23222025-04-011511810.1038/s41598-025-99273-5Clinical performance validation and four diagnostic strategy assessments of high-sensitivity troponin I assaysJunyi Wu0Yaotong Hua1Yilin Ge2Ke Chen3Siyu Chen4Jiashu Yang5Hui Yuan6Department of Laboratory Medicine, Beijing Anzhen Hospital, Capital Medical UniversityDepartment of Laboratory Medicine, Beijing Anzhen Hospital, Capital Medical UniversityDepartment of Laboratory Medicine, Beijing Anzhen Hospital, Capital Medical UniversityDepartment of Laboratory Medicine, Beijing Anzhen Hospital, Capital Medical UniversityDepartment of Laboratory Medicine, Beijing Anzhen Hospital, Capital Medical UniversityDepartment of Laboratory Medicine, Beijing Anzhen Hospital, Capital Medical UniversityDepartment of Laboratory Medicine, Beijing Anzhen Hospital, Capital Medical UniversityAbstract Acute coronary syndrome (ACS) includes conditions such as unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI). High-sensitivity cardiac troponin I (hs-cTnI) assays have been recommended as primary biomarkers for NSTEMI diagnosis due to their high sensitivity and specificity. However, there is no consensus on the optimal diagnostic strategy for early NSTEMI detection. This study aims to evaluate the diagnostic performance of four hs-cTnI-based strategies for suspected NSTEMI: Limit of Detection (LoB), Single Cut-off, hs-cTnI 0/1 h Algorithm, and hs-cTnI 0/2 h Algorithm, in a Chinese cohort and compare the performance of assays from different manufacturers. Performance verification was conducted, including LoB, LoD, LoQ, and precision analysis. Clinical samples from 267 ACS patients were analyzed using Hybiome hs-cTnI assays. Diagnostic accuracy was assessed based on sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1-score. The LoB strategy demonstrated 100% sensitivity but low PPV (14.0%). Both the hs-cTnI 0/1 h Algorithm and hs-cTnI 0/2 h Algorithm showed high diagnostic performance, with the 0/2 h algorithm providing the best overall. 89.0% accuracy, 93.3% sensitivity, and 73.68% F1-score. The hs-cTnI 0/2 h Algorithm offers the most reliable diagnostic performance for early NSTEMI diagnosis.https://doi.org/10.1038/s41598-025-99273-5NSTEMIhs-cTnIDiagnostic strategy
spellingShingle Junyi Wu
Yaotong Hua
Yilin Ge
Ke Chen
Siyu Chen
Jiashu Yang
Hui Yuan
Clinical performance validation and four diagnostic strategy assessments of high-sensitivity troponin I assays
Scientific Reports
NSTEMI
hs-cTnI
Diagnostic strategy
title Clinical performance validation and four diagnostic strategy assessments of high-sensitivity troponin I assays
title_full Clinical performance validation and four diagnostic strategy assessments of high-sensitivity troponin I assays
title_fullStr Clinical performance validation and four diagnostic strategy assessments of high-sensitivity troponin I assays
title_full_unstemmed Clinical performance validation and four diagnostic strategy assessments of high-sensitivity troponin I assays
title_short Clinical performance validation and four diagnostic strategy assessments of high-sensitivity troponin I assays
title_sort clinical performance validation and four diagnostic strategy assessments of high sensitivity troponin i assays
topic NSTEMI
hs-cTnI
Diagnostic strategy
url https://doi.org/10.1038/s41598-025-99273-5
work_keys_str_mv AT junyiwu clinicalperformancevalidationandfourdiagnosticstrategyassessmentsofhighsensitivitytroponiniassays
AT yaotonghua clinicalperformancevalidationandfourdiagnosticstrategyassessmentsofhighsensitivitytroponiniassays
AT yilinge clinicalperformancevalidationandfourdiagnosticstrategyassessmentsofhighsensitivitytroponiniassays
AT kechen clinicalperformancevalidationandfourdiagnosticstrategyassessmentsofhighsensitivitytroponiniassays
AT siyuchen clinicalperformancevalidationandfourdiagnosticstrategyassessmentsofhighsensitivitytroponiniassays
AT jiashuyang clinicalperformancevalidationandfourdiagnosticstrategyassessmentsofhighsensitivitytroponiniassays
AT huiyuan clinicalperformancevalidationandfourdiagnosticstrategyassessmentsofhighsensitivitytroponiniassays